Atomoxetine

MECHANISM OF ACTION 

Atomoxetine acts as a selective norepinephrine reuptake inhibitor by blocking the norepinephrine transporter in the brain, which increases the availability of Norepinephrine in the synaptic cleft. This enhanced norepinephrine activity, particularly in the prefrontal cortex, improves attention, concentration, and impulse control in individuals with ADHD. Additionally, atomoxetine indirectly raises levels of Dopamine in this region without significantly affecting reward pathways, making it effective while having a lower risk of abuse compared to stimulant medications.

PHARMACOKINETICS

Absorption 

Atomoxetine is well absorbed after oral administration, with peak plasma concentrations typically reached within 1–2 hours. It has a high oral bioavailability, although this can vary depending on individual metabolic differences, particularly due to genetic variations in liver enzymes such as CYP2D6. Food does not significantly affect the extent of absorption, though it may slightly delay the rate at which peak concentration is achieved. Overall, atomoxetine’s absorption profile supports consistent therapeutic levels with regular dosing.

Distribution 

Atomoxetine is widely distributed throughout the body after absorption. It is highly bound to plasma proteins (about 95–98%), primarily to albumin, which helps maintain stable circulating levels of the drug. Atomoxetine readily crosses the blood–brain barrier, allowing it to exert its therapeutic effects within the central nervous system. Its volume of distribution indicates extensive tissue uptake, supporting effective action in brain regions such as the prefrontal cortex that are involved in attention and behavioral regulation.

Metabolism 

Atomoxetine is primarily metabolized in the liver by the enzyme CYP2D6. It is converted into an active metabolite, 4-hydroxyatomoxetine, which is further processed into inactive forms. The rate of metabolism varies among individuals due to genetic differences in CYP2D6, leading to higher drug levels and prolonged action in poor metabolizers compared to normal metabolizers.

Elimination 

Atomoxetine is primarily eliminated through the urine, mostly as inactive metabolites formed in the liver. The half-life of atomoxetine varies with CYP2D6 metabolism: approximately 5 hours in extensive metabolizers and 20 hours in poor metabolizers, which affects dosing frequency. Small amounts of unchanged drug are also excreted in the urine.

PHARMACODYNAMICS 

Atomoxetine works by selectively inhibiting the reuptake of norepinephrine in the central nervous system, increasing its availability in the synaptic cleft. This enhanced norepinephrine signaling in the prefrontal cortex improves attention, executive function, and impulse control in patients with ADHD. Atomoxetine also indirectly increases dopamine levels in the prefrontal cortex without significantly affecting the striatal dopamine pathways, which reduces its potential for abuse compared to stimulant medications. Its pharmacodynamic effects develop gradually, often requiring several weeks of consistent dosing for full therapeutic benefit.

ADMINISTRATION 

Atomoxetine is administered orally in the form of capsules. It can be taken with or without food, though taking it with food may reduce stomach upset. The usual dosing is once or twice daily, depending on patient weight and response, with the total daily dose often calculated based on mg per kg of body weight in children and adolescents. Consistent daily administration is important to maintain steady therapeutic levels, and dose adjustments may be necessary for patients with liver impairment or for those who are poor metabolizers of CYP2D6.

DOSAGE AND STRENGTH 

Atomoxetine is available in capsule form with strengths ranging from 10 mg to 100 mg. In children and adolescents, the typical dose is 0.5–1.2 mg/kg/day, administered once or twice daily, with gradual titration based on response and tolerability. Adults usually start at 40 mg/day, which can be increased to 80 mg/day after a few days, with some patients requiring up to 100 mg/day for optimal effect. Dosing adjustments may be necessary depending on body weight, liver function, and CYP2D6 metabolizer status to ensure safe and effective treatment.

DRUG INTERACTIONS 

Atomoxetine is mainly metabolized by CYP2D6, so inhibitors of this enzyme (like fluoxetine or paroxetine) can raise its levels. It should not be used with MAOIs and may increase blood pressure or heart rate if combined with other sympathomimetic drugs.

FOOD INTERACTIONS 

Atomoxetine can be taken with or without food, as food does not significantly affect its absorption. Taking it with meals may reduce stomach upset, but there are no major dietary restrictions or interactions reported.

CONTRAINDICATIONS 

Atomoxetine should not be used in patients with hypersensitivity to the drug, concurrent or recent MAOI use, narrow-angle glaucoma, or severe cardiovascular disorders. Caution is needed in those with psychiatric conditions, liver impairment, or CYP2D6 poor metabolizer status.

SIDE EFFECTS 

Common side effects:

• Nausea and vomiting 

• Decreased appetite 

• Fatigue 

• Dizziness 

• Dry mouth 

• Sleep disturbances 

Cardiovascular effects:

• Increased heart rate 

• Mild elevation in blood pressure 

Rare but serious side effects:

• Liver injury 

• Suicidal thoughts (especially in children and adolescents) 

• Severe cardiovascular events

TOXICITY 

Toxicity from Atomoxetine is uncommon but can occur in overdose. Symptoms may include somnolence, vomiting, tachycardia, hypertension, tremor, and agitation. Severe cases can lead to coma, seizures, or cardiovascular complications. Treatment is primarily supportive, including monitoring vital signs, gastric decontamination if early, and managing cardiovascular or neurological symptoms. There is no specific antidote for atomoxetine overdose.